Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline.

[2] While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.

[3] Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.